Comparative Pharmacology
Head-to-head clinical analysis: SULFACEL 15 versus SULFAIR 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACEL 15 versus SULFAIR 15.
SULFACEL-15 vs SULFAIR-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate, thereby inhibiting folate synthesis and bacterial growth.
Sulfadoxine is a long-acting sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. Pyrimethamine inhibits dihydrofolate reductase, synergistically inhibiting nucleic acid synthesis in Plasmodium species.
Adults: 15 mg/kg orally every 6 hours for 10 days; maximum single dose 1 g.
15 mg orally every 6 hours, not to exceed 60 mg/day.
None Documented
None Documented
Expected ~6-9 hours based on related sulfacetamide; however, no specific data for SULFACEL-15. Clinical context: prolonged in renal impairment.
12–15 hours in healthy adults; prolonged to 20–30 hours in moderate hepatic impairment.
Renal: ~85-90% unchanged; Biliary/Fecal: ~5-10% (metabolites and unchanged drug); ~5% eliminated via feces following biliary secretion.
Renal excretion unchanged: 70%; hepatic metabolism to inactive metabolites: 20%; fecal excretion: 10%.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)